Gabon longs to cash in on sacred hallucinogenic remedy
For centuries, religious devotees have eaten it -- a psychotropic shrub that users say has addiction-fighting powers.
It fascinates foreign visitors, psychiatric patients and rich pharmaceutical companies that want to market it.
Now this central African country, where its use is enshrined in ancestral tradition, is scrambling to avoid missing out on the boom.
Teddy Van Bonda Ndong, 31, an initiate in the Bwiti spiritual tradition, calls it "sacred wood". He consumes it in small amounts daily, he said, for his "mental and physical health".
"It has a lot of power to help human beings," added Stephen Windsor-Clive, a 68-year-old retiree.
"It's untapped. A mysterious force lies within this plant."
He travelled to Gabon from Britain and consumed iboga -- in a powder ground from its roots -- during a 10-day Bwiti ceremony.
He tried it with a view to adopting it as a treatment for his daughter, who suffers from mental illness.
- Economic potential -
Given the interest, Gabon is seeking to channel the plant onto the international marketplace.
Exports of iboga products, including its active ingredient ibogaine, are few and strictly regulated in the country.
It grows mostly in the wild, but "more and more effort is being made to domesticate the plant", said Florence Minko, an official in the forestry ministry.
Potentially toxic in high doses, ibogaine can have effects similar to LSD, mescaline or amphetamines, and cause anxiety and hallucinations.
But users believe it can help drug addicts kick their habit and treat post-traumatic stress and neurological illnesses.
Yoan Mboussou, a local microbiologist and Bwiti initiate, hopes to gain an export licence for the 500-milligram ibogaine capsules he produces at his laboratory near the capital Libreville.
He sells them in Gabon as a food supplement, declaring them to have "anti-fatigue, antioxidant and anti-addictive" qualities.
Iboga, he believes, "is a potential lever to develop the economy and the whole country".
- Tradition and IP -
Countries such as the United States and France class iboga as a narcotic because of health risks identified in studies, especially heart issues. But it is used in treatment centres in countries including the Netherlands, Mexico and Portugal.
Numerous studies have examined its effects -- both helpful and harmful -- and scientists have taken out dozens of international patents for ibogaine therapeutic treatments.
"Most of those are based on studies of iboga use by Gabonese people, particularly by Bwiti practitioners," said Yann Guignon, from the Gabonese conservation group Blessings Of The Forest.
Despite the plant's "colossal therapeutic benefits", "Gabon is clearly missing out on the economic potential of iboga," he added.
"It did not position itself in this market in time by developing productive iboga plantations, a national processing laboratory and a proper industrial policy."
Overseas laboratories meanwhile have worked out how to make synthetic ibogaine and to extract it from other plants, such as Voacanga africana.
That flowering tree is available in greater quantities in Ghana and Mexico, which "can produce ibogaine at unbeatable prices", said Guignon.
And "Gabonese traditional knowledge is not protected by intellectual property regulations."
Currently only one company in Gabon has a licence to export iboga products -- though Minko, from the forestry ministry, said the country hopes this number will rise in the coming years.
She said companies were likely to produce more, spurred by revenue guarantees under the Nagoya Protocol, an international agreement on biological diversity and resource-sharing.
She wants the country to obtain a "made in Gabon" certificate of origin for iboga.
"This is a huge resource for Gabon. We have drawn up a national strategy for the conservation and sustainable use of the product," she said.
"Gatherings will soon be organised, bringing together all the groups concerned: NGOs, traditional practitioners and scientists."
- Soothing properties -
After harvesting iboga to the sound of traditional harps and consuming it in the initiation ceremony, Stephen Windsor-Clive was convinced by the benefits of iboga.
"I definitely want to bring my daughter here and have her have the experience," he said.
"This is my last attempt to find something which might be of assistance to her."
Another visitor, Tafara Kennedy Chinyere, travelled from Zimbabwe to discover Gabon and found, in the initiation, relief from anxiety and his "inner demons".
"I feel good in my body, in myself," he said, sitting under a tree after the ceremony.
"I feel like the iboga helped me to let go of things that you no longer need in your life."
lnf/emp/rlp/kjm/phz
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
I Quit Drinking. It's Great. There's Just One Small Problem.
Ask A.J. is Slate's advice column on addiction, recovery, and how to hate yourself less. It's anonymous! Dear A.J., What helps you with your 'emotional sobriety'? I've found not drinking to be relatively easy (after bingeing and blacking out on booze for 20 years), but dealing with life without pouring whiskey all over my feelings—that's been a challenge. How do you not become a 'dry drunk'? —Can't Stop the Music Dear Can't Stop, This is a question that plagues so many newly sober people who have put down their booze but have traded it for constant agitation and world-weariness. Before we start, let's get some traditional interpretations for both 'emotional sobriety' and 'dry drunk' that will not require readers to power through the 12-Step Program in the next five minutes to understand this column. Bill Wilson, the founder of Alcoholics Anonymous, coined the term emotional sobriety, which, in simple terms, can be defined as inner peace. After many years without a drink, Wilson experienced a bout of depression which almost drove him to a disastrous relapse. Then he wrote Emotional Sobriety: The Next Frontier, which, in my opinion, is the one piece of AA literature that is the most valuable to nonalcoholic civilians. Now, dry drunk is a term that I believe people are more familiar with. It's a way to describe an alcoholic who may no longer drink but still exhibits noxious and destructive behavior. What's the point of not drinking if all your friends and family find you an insufferable dickhead and no longer want to hang around with you? It's a puzzle, for sure. In order to deal with life without pouring whiskey all over your feelings, you have to—have to—stick with your routine of things that make you feel like a good, balanced person. Ideally, you do all the sometimes-sort-of-boring maintenance stuff before things get out of whack. I believe the best way to avoid drunk dryness is by attending AA meetings, doing the steps, sponsoring, etc. If you commit to a 12-Step program and do it the way you're supposed to, you'll likely keep your worst instincts in check. If not AA, you need some kind of practice that keeps you grounded, and on top of that, you need to take care of your physical self. I know that when I haven't been to an AA meeting or the gym or when my sleep is off or I'm eating cheesecake for dinner, it's probably too late. Then, from there, it's only a matter of time before my emotional sobriety is in the toilet. Here are some patterns of behavior that are always surefire signs I'm completely off. Yes, I've kicked that little droid monster across the kitchen floor. Not proud of it—and I do not recommend it, as those things are deceptively heavy. And once I'm violent toward the Robovac, I know there's a good chance I will embarrass myself by acting truly horrid toward a human being soon after that. I mean, I won't kick anyone, but I can definitely end some friendships when I'm in that mode. You probably have your own version of these warning signs. When you start seeing them, the key to avoiding overload is to do some game planning. First, let's identify all the things that may activate your discomfort: the way your boss blatantly undermines you on Zoom calls in front of your co-workers, your mother-in-law's opinions about your parenting, the exorbitant cost of Oasis tickets even though they don't change their set list—whatever it may be. That way, you'll know when you're headed into a situation that could potentially cause the worst version of you to show up and wreck the place. And if you do practice the 12 Steps, remind yourself that if you act out, you're destined to have to make amends if you take something too far. (If you don't practice the 12 Steps, well, you probably don't want to have to explain to HR why you yelled on a Zoom call either.) Then, you have to recenter, before/after heading into one of those challenging situations. For me, the best things that slow down my brain and keep me grounded are pretty simple and obvious: meditation, Brazilian jujitsu, and long walks with a weighted vest on. (I know—don't judge.) When I'm consistent with those, I'm softer and more considerate of others. But exercise, mindfulness, putting your phone down and playing with your dog, whatever you like to do—those tools are there for you at any time. You can always choose to turn to them instead of acting out. The other cooling-off method I like is popular in Buddhism, found in nearly every Pema Chödrön greatest hits compilation. Whenever you feel hatred, replace it with love. (This is also a popular refrain from the St. Francis prayer, which is a fantastic decompressive go-to at boiling point.) If you're going to go that route, you must make sure it's genuine and not in that condescending Southern aristocratic bless-his-heart way, because that attitude leaves a heavy weight on your soul as well. Here's a great prayer I've learned over the years that, when I'm on my A game, I begin my mornings with and carry with me throughout the day: 'Let your thoughts be my thoughts, let your words be my words, let your actions be my actions.' The word your in the prayer doesn't necessarily have to refer to God or a higher power. Still, it does have to be whatever brings out the best version of you—the most rational version of you. It's crucial that you can flip the switch over to that version of you as quickly as you can to the worst version. Stopping drinking is only the beginning here; the most challenging part is not letting your drunk escape. But I think you know this already. Just put the extra effort into reminding yourself of it every day. Solve the daily Crossword
Yahoo
16 hours ago
- Yahoo
I won't ever sit back and declare ‘job done', says drugs minister
Drugs minister Maree Todd has said she will never 'sit back, relax and say 'job done'' in the fight against drug deaths. Ms Todd was appointed to the role in June following the death of Christina McKelvie earlier this year from secondary breast cancer. Despite the circumstances of the appointment, the former mental health pharmacist said she was 'excited' to move from the social care brief to drugs as the Government continues its push to tackle the level of addiction and death across Scotland. The minister inherits a legacy which has been long-criticised by opponents, with Scotland having the highest drug death rates in Europe – a figure which actually increased between 2022 and 2023 in the latest available confirmed data. Just this week, figures showed the number of suspected drug deaths between March and May of this year increased by 15% compared to the previous 13 weeks. Speaking to the PA news agency, the minister said there is a 'consensus' that 'the work we are doing is the right kind of work', but the Government is responding to a 'changing landscape'. When the Government launched its national mission on drugs under the premiership of Nicola Sturgeon, the focus was largely on opioids such as heroin. But that has shifted, reflecting an increase in the injection of cocaine and the spectre of synthetic opioids known as nitazenes. On the latter, the minister said: 'They are unbelievably potent, super-strong, very tiny amounts can cause fatal overdoses easily.' As it looks to deal with the shifting threat posed by drugs, she stressed the need for the Government to be 'agile'. Ms Todd said: 'We've just had our rapid action drug alerts and response (Radar) statistics released this week and we've seen a rise in deaths, a rise in Naloxone use, a rise in hospital admissions. 'We are seeing some absolutely significant and tangible harm occurring because of the change in the drug supply. 'I suppose the lesson that provides to me is that we need to be agile. 'I don't think we do one thing and this job is done and we fixed the problem that Scotland faces, we have to continually look carefully at what's happening in Scotland, understand the challenges that we're facing, understand the harms that people are experiencing.' She added: 'I don't think I would ever sit back and relax and say 'job done'. 'I think we've seen some significant progress, but each of these deaths is an absolute tragedy – it's a family who's lost a loved one, it's a loss of potential and contribution to our communities.' The way forward, she said , is a job for the whole of Government, saying there is a need for 'primary prevention'. The minister said: 'We need to be thinking, why is it that Scotland faces this challenge and what can we do to shift the likelihood that people growing up in Scotland will turn to drugs and alcohol as they grow older?' Earlier this year, the Thistle Centre opened in the east end of Glasgow, a UK-first safe consumption room giving those struggling with addiction a safe place to inject drugs. Since opening, the facility has supervised 3,008 injecting episodes and dealt with 39 medical emergencies, which could include administering Naloxone or even resuscitation. 'People would definitely have died if they had not been in that unit,' Ms Todd said. 'I think in March, there was a cluster of very profound overdose episodes, I think this is the issue with nitazenes, they act very fast, so people were really unwell really quickly and it takes a lot of Naloxone because of its potency.' In other parts of Scotland without the benefit of a safe consumption room where that specific batch of drug was used, the minister said: 'Where people used it, they did die.'
Yahoo
a day ago
- Yahoo
Alnylam reaches new highs on strong sales of closely watched rare disease drug
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Sales of an Alnylam Pharmaceuticals rare disease medicine substantially outpaced Wall Street expectations in the drug's first full quarter since U.S. regulators expanded its use, lifting the biotechnology company's market value to new highs on Thursday. According to Alnylam, sales of the drug, called Amvuttra and sold for two types of transthyretin amyloidosis, or ATTR, reached $492 million between April and June, well above consensus estimates of about $350 million. About $150 million of that total was attributed to patients with the 'cardiomyopathy' form of the disease that regulators cleared Amvuttra for in March. Some 1,400 people were on therapy at the end of the quarter, Alnylam said. Alnylam also hiked its 2025 financial projections by hundreds of millions of dollars, guiding between $2.18 billion and $2.28 billion in net revenue from Amvuttra and Onpattro, its other transthyretin amyloidosis drug, compared to the previous $1.6 billion to $1.73 billion range. Alnylam now expects $2.65 billion to $2.8 billion in total net revenues. Company shares climbed by more than 15%, taking Alnylam's market value past $50 billion. Dive Insight: Alnylam has for years been among biotech's most valuable companies. But it has never been consistently profitable, and is banking on Amvuttra to change that. A March expansion into ATTR cardiomyopathy, a progressive condition that causes heart failure, hospitalizations and death, was a vital step. ATTR cardiomyopathy is believed to be more common than the 'polyneuropathy' form Amvuttra was first cleared to treat in 2022. Sales of the leading cardiomyopathy treatment, Pfizer's tafamidis, topped $5 billion last year. Amvuttra, an injectable medicine, competes with Pfizer's drug and BridgeBio Pharma's Attruby, both of which are taken orally. Attruby reached market earlier and is also off to a faster-than-expected start. Alnylam priced Amvuttra in cardiomyopathy at $476,000 per year, a significant premium to its rivals, despite the fact clinical results didn't appear strong enough to indicate its drug is clearly superior. Alnylam executives have said they expect Amvuttra to grow the market for ATTR cardiomyopathy medicines, as most patients still aren't on treatment. They've also expressed confidence Amvuttra could become a standard option. The drug works differently than its competitors and, because it's only injected four times a year, could have better adherence, they've said. So far, its optimistic projections appear to be playing out. On a conference call Thursday, some analysts questioned whether the better-than-expected numbers were driven by a surge of initial prescriptions for sicker people whose disease had been progressing on other medicines. CEO Yvonne Greenstreet said the company is seeing 'broad uptake' that includes newly diagnosed patients as well. Chief Commercial Officer Tolga Tanguler added many commercial and Medicare insurers already have policies out and are clearing use in newly diagnosed patients, indicating they aren't requiring people take Pfizer or BridgeBio's drugs first. A month into the quarter, Alnylam began to see a 'very healthy and accelerating trend in first-line use,' he said. The results are 'not just a flash in the pan,' Greenstreet added. 'We expect continuous, sustainable growth,' she said. Following the call, Stifel analyst Paul Matteis wrote in a research note the higher guidance still 'looks beatable' and raised his projections for Amvuttra's peak annual sales to $9 billion, up from about $7 billion previously. Alnylam intends to gradually lower Amvuttra's net price through rebates and pay-for-performance deals as patient uptake increases. On Thursday's call, CFO Jeff Poulton said to expect a 'mid-single digit reduction in net price' this year. Recommended Reading BridgeBio sales of new heart drug outstrip expectations Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data